This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Looking at the FDA approval of the Eversense 365 implantable Continuous Glucose Monitor from Senseonics

Ticker(s): SENS, ABT, DXCM, MDT

Who's the expert?

Institution: Premier Endocrinology

  • Private practice endocrinologist at Premier Endocrinology.
  • Manages 100-200 patients with obesity and type 2 diabetes.

Interview Questions
Q1.

Please describe your background and patient setting

Added By: ben_admin
Q2.

How many patients do you manage who utilize a CGM device?

Added By: ben_admin
Q3.

What are the most popular CGM devices used today?

Added By: ben_admin
Q4.

What is your opinion of the Eversense 365 CGM?

Added By: ben_admin
Q5.

How likely are you to prescribe the Eversense CGM ?

Added By: ben_admin
Q6.

Can you provide an overview of the different CGMs available on the market for patients? What are the differences between these CGMs, and what do you attribute the popularity of Dexcom and FreeStyle Libre to compared to others like Eversense?

Added By: slingshot_insights
Q7.

How involved is the procedure to place the implantable Eversense CGM? Is it a minor procedure, and are there specific risks or barriers, such as infection or patient preference? Does it integrate with popular pumps, and how does the accuracy of the implantable CGM compare to others?

Added By: slingshot_insights
Q8.

How does insurance coverage impact CGM selection for patients? Is the cost of Eversense comparable to other CGMs, and do you expect to increase your use of Eversense in the future given its features and support?

Added By: slingshot_insights

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.